Active Stocks
Thu Feb 29 2024 15:49:54
  1. Kotak Mahindra Bank share price
  2. 1,690.80 0.43%
  1. Axis Bank share price
  2. 1,075.70 0.10%
  1. Tata Steel share price
  2. 140.90 0.11%
  1. Power Grid Corporation Of India share price
  2. 282.55 1.07%
  1. ITC share price
  2. 406.50 -0.51%
Business News/ Companies / News/  Abbott India recalls antacid Digene Gel, DCGI issues advisory
BackBack

Abbott India recalls antacid Digene Gel, DCGI issues advisory

State drugs controllers have been advised to keep strict vigil on the movement, sale and distribution and stock of the said products in the market, draw samples if the product is lying in the market, and initiate necessary action

Abbott India recalls antacid Digene GelPremium
Abbott India recalls antacid Digene Gel

New Delhi: Drugmaker Abbott India has voluntarily recalled several batches of antacid Digene Gel, following which the Drug Controller General of India (DCGI) issued an advisory against using the product. The regulator said that the impugned product, manufactured at the company’s Goa unit, may be unsafe, and could result in adverse effects when consumed.

DCGI had received a complaint on 9 August, alleging bitter taste and pungent odour of the antacid.

Simultaneously, the government has advised doctors to avoid prescribing the medicine to patients and educate them on possible adverse reactions on consumption of the product.

“Patients to discontinue Digene Gel which are manufactured at Goa facility," the communication said adding that all wholesalers and retailers have also been asked to remove the product from distribution and sale.

“Abbott in India has voluntarily recalled Digene Gel antacid medicine manufactured at our Goa site, due to isolated customer complaints on taste and odour. There have been no reports of patient health concerns. Other forms of Digene, such as tablets and stick packs are not impacted and Digene Gel manufactured at our other production site is not affected and continues to be available in sufficient quantities to meet current demand," said a spokesperson of Abbott in a reply to Mint’s query.

State drugs controllers have been advised to keep strict vigil on the movement, sale and distribution and stock of the said products in the market, draw samples if the product is lying in the market, and initiate necessary action as per the provisions of the Drugs and Cosmetic Act and Rules.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

ABOUT THE AUTHOR
Priyanka Sharma
Priyanka Shamra is a health and pharma journalist with nearly nine years of field reporting experience. She is a special correspondent with Mint. Her beat includes covering the Ministry of Health and Department of Pharmaceuticals. She also covers the Ministry of Women and Child Development and the Department of Biotechnology.
Catch all the Corporate news and Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 06 Sep 2023, 01:01 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App